Mycophenolate mofetil therapy for refractory inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 13, Issue 12, 2007, Pages 1488-1492

  Palaniappan, S ^a   Ford, A C ^b   Greer, D ^a   Everett, S M ^a   Chalmers, D M ^a   Axon, A T R ^a   Hamlin, P J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; Inflammatory bowel disease; Mycophenolate; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BEHAVIOR CHANGE; COLON CROHN DISEASE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IRRITABILITY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL RECORD REVIEW; PANCREATITIS; PRIORITY JOURNAL; RASH; REMISSION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES;

EID: 38049014413     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20258     Document Type: Article

References (28)

1. Kho YH, Oudkerk P, Jansman FGA, et al. Pharmacotherapeutic options in inflammatory bowel disease: an update. Pharm World Sci. 2001;23(1):17-21.
2. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-362.
3. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta analysis. Ann Intern Med. 1995;122:132-142.
4. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine and 6 mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev. 2000;CD000545.
5. Pearson DC, May GR, Fick GH, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000;CD000067.
6. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-489.
7. Behrend M. A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation. Clin Nephrol. 1996;45:336-341.
8. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation. 1993;56:75-82.
9. Kobashigawa J, Miller L, Renlund D, et al. A randomised active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation. 1998;66:507-515.
10. Nousari HC, Sragivich A, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol. 1999;40:265-268.
11. Kitchin JE, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects and potential uses. J Am Acad Dermatol. 1997;37:445-449.
12. Orth T, Peters M, Schlaak JF, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol. 2000;95:1201-1207.
13. Fickert P, Hinterleitner TA, Wenzl HH, et al. Mycophenolate mofetil in patients with Crohn's disease. Am J Gastroenterol. 1998; 93:2529-2532.
14. Neurath MF, Wanitschke R, Peters M, et al. Randomised trial of mycophenolate mofetil versus azathioprinefor treatment of chronic active Crohn's disease. Gut. 1999;44:625-628.
15. Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflammatory Bowel Dis. 2000;6:16-20.
16. Fellerman K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:171-176.
17. Hafraoui S, Dewit O, Marteau P, et al. Mycophenolate mofetil in refractory Crohn's disease after failure of treatment by azathioprine or methotrexate. Gastroenterol Clin Biol. 2002;26:17-22.
18. Skelly MM, Logan RF, Jenkins D, et al. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2002; 8:93-97.
19. Wenzl HH, Hinterleitner TA, Aichbichler BW, et al. Mycophenolate mofetil for Crohn's disease: Short term efficacy and long term outcome. Aliment Pharmacol Ther. 2004;19:427-434.
20. Ford AC, Towler R J, Moayyedi P, et al. Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:1365-1369.
21. Radford-Smith GL, Taylor P, Florin TH. Mycophenolate mofetil in IBD patients. Lancet. 1999;354:1386-1387.
22. Sanquer S, Breil M, Baron C, et al. Induction of inosine monophosphate dehydrogenase activity after long term treatment with mycophenolate mofetil. Clin Pharmacol Ther. 1999;65:640-648.
23. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
24. Weersma RK, Peters FT, Oostenburg LE, et al. Increased incidence of azathioprine- induced pancreatitis in Crohn's Disease compared with other diseases. Aliment Pharmacol Ther. 2004;20:843-850.
25. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo controlled trial. Hepatogastroenterology. 1999;46:1724-1729.
26. Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1597-1604.
27. Solinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995;60:225-232.
28. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321-1325.